Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer
PITTSBURGH , Sept. 17, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the early tender results of the previously announced cash tender offer (the "Maxi...
Viatris Announces Cash Tender Offers for Certain Outstanding Notes
PITTSBURGH , Sept. 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that it and its subsidiaries, Mylan Inc. ("Mylan") and Utah Acquisition Sub Inc. (...
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock Down
Viatris (VTRS) Q1 numbers fall short of estimates. The company adjusts the annual guidance to reflect the impact of divestitures.
Viatris (VTRS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compar...
Viatris (VTRS) Q1 Earnings and Revenues Miss Estimates
Viatris (VTRS) came out with quarterly earnings of $0.67 per share, missing the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago.
Viagra maker Viatris misses revenue estimates on weak demand for older drugs
Drugmaker Viatris narrowly missed first-quarter revenue estimates on Thursday, hurt by weak sales for its older drugs such as cholesterol medication Lipitor and Norvasc for high blood pressure.
Why Earnings Season Could Be Great for Viatris (VTRS)
Viatris (VTRS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential
Viatris Inc. is a deep value pharmaceutical company with a low valuation and a 4.1% yield. Viatris has seen a slowdown in top line decline and has a promising pipeline of potential blockbuster drug...
Viatris Stock Is Still Worth Buying
Viatris Inc. stock has risen by 26.7% since my November 2023 bullish call, outperforming the S&P 500 Index. It's time to update my thesis - read on. Although net sales declined (as did EBITDA and n...
Why Is Viatris (VTRS) Down 3.5% Since Last Earnings Report?
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?
Is Viatris a Great Dividend Stock or Just a Value Trap?
Viatris' high dividend yield and low valuation may look attractive to bargain hunters. However, the company's earnings nosedived last year, causing investor concern.
US FDA declines to approve Viatris's injection for multiple sclerosis
The U.S. FDA has declined to approve Viatris and Mapi Pharma's once-a-month injection for treating relapsing forms of multiple sclerosis (MS), the companies said on Monday.
Related Companies